Toward Informed User Decisions About Pharmacological Cognitive Enhancement

Area of Science:

• Neuroscience
• Bioethics
• Pharmacology

Background:

• Pharmacological cognitive enhancement (PCE) is the use of pharmaceuticals to boost cognitive function for non-therapeutic purposes.
• Current PCE use, particularly of stimulants like methylphenidate and modafinil, is prevalent but often occurs without medical oversight.

Purpose of the Study:

• To analyze the complexities of informed decision-making regarding PCE.
• To examine the equitable distribution of risks and benefits associated with PCE.
• To explore potential solutions for improving the safety and accessibility of PCE information.

Main Methods:

• The study presents a critical analysis of the ethical and practical challenges of PCE.
• It reviews existing literature on the use of prescription medications for cognitive enhancement.
• The author employs a risk-benefit analysis framework to evaluate PCE decision-making.

Main Results:

• Informed decision-making about PCE is hindered by a lack of accessible, nuanced risk-benefit analyses for many users.
• The risks and benefits of PCE are inequitably distributed due to various direct and indirect barriers.
• Even with equitable distribution of PCE drugs, their associated risks and benefits remain unevenly spread.

Conclusions:

• PCE is not always in the user's best interest due to challenges in risk-benefit assessment and inequitable distribution.
• Future PCE pharmaceuticals are likely to present similar challenges.
• Clinical consultations and e-health solutions offer potential, albeit cautious, avenues for ameliorating the situation.